Scalp Dermatoses
Also Known As:
Scalp Dermatosis; Dermatoses, Scalp; Dermatosis, Scalp
Networked: 10
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Disease Context: Research Results
Related Diseases
Experts
| 1. | Blalock, Travis W:
1 article
(01/2012)
|
| 2. | Davis, Loretta S:
1 article
(01/2012)
|
| 3. | Turrentine, Jake E:
1 article
(01/2012)
|
| 4. | Kircik, Leon:
1 article
(01/2010)
|
| 5. | García-Vargas, Alejandro:
1 article
(08/2007)
|
| 6. | Sandoval-Tress, Cecilia:
1 article
(08/2007)
|
| 7. | Mayorga-Rodríguez, Jorge Arturo:
1 article
(08/2007)
|
| 8. | Gottlieb, Alice B:
1 article
(05/2003)
|
| 9. | Ford, Rosanne Odom:
1 article
(05/2003)
|
| 10. | Spellman, Mary C:
1 article
(05/2003)
|
Drugs and Biologics
Drugs and Important Biological Agents (IBA) related to Scalp Dermatoses:
| 1. | Adrenal Cortex Hormones (Corticosteroids)IBA
|
| 2. | Griseofulvin (Grifulvin V)FDA LinkGeneric
|
| 3. | Betamethasone (Celestone)FDA Link
01/01/2003
- " A new formulation of betamethasone valerate 0.1% in a thermophobic, low-residue, foam vehicle (Bettamousse) (BVM) has become available for the topical treatment of scalp dermatoses. " 01/01/2003
- " A new formulation of betamethasone valerate 0.12% in a thermophobic, low-residue foam vehicle (Bettamousse trade mark, Mipharm, Italy; BVM) is available for the treatment of scalp dermatoses. " 06/01/2000
- " A new preparation of betamethasone valerate in a novel foam vehicle is available for treatment of scalp dermatoses. " 07/01/2001
- " Although betamethasone valerate (BMV) foam, 0.12% (Luxiq, Connectics Corporation, Palo Alto, CA) is approved by the Food and Drug Administration for the treatment of corticosteroid-responsive scalp dermatoses, no data are available for its use on nonscalp psoriasis. "
|
| 4. | Clobetasol (Clobetasol Propionate)FDA LinkGeneric
|
| 5. | tebufenozide (Mimic)IBA
|
|
Therapies and Procedures